Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns

Pediatrics

Volumn 134, Issue 3, 2014, Pages 504-509

  Kuzniewicz, Michael W ^a,b   Wickremasinghe, Andrea C ^b,c   Wu, Yvonne W ^b   McCulloch, Charles E ^b   Walsh, Eileen M ^a   Wi, Soora ^a   Newman, Thomas B ^a,b  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

Hyperbilirubinemia; Kernicterus; Neonate; Neurotoxicity

Indexed keywords

GLUCOSE 6 PHOSPHATE DEHYDROGENASE;

ARTICLE; CAUSAL ATTRIBUTION; CEREBRAL PALSY; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; KERNICTERUS; MALE; NEONATAL HYPERBILIRUBINEMIA; NEUROTOXICITY; NEWBORN; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PERCEPTION DEAFNESS; RISK FACTOR; UNITED STATES; FOLLOW UP; HYPERBILIRUBINEMIA; INCIDENCE; TREATMENT OUTCOME;

HYPERBILIRUBINEMIA; KERNICTERUS; NEONATE; NEUROTOXICITY;

FEMALE; FOLLOW-UP STUDIES; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; HYPERBILIRUBINEMIA; INCIDENCE; INFANT, NEWBORN; MALE; TREATMENT OUTCOME;

EID: 84907214305     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-0987     Document Type: Article

References (36)

1. Maisels MJ, Baltz RD, Bhutani VK, et al; American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297-316
2. Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant ≥35 weeks' gestation: an update with clarifications. Pediatrics. 2009;124(4):1193-1198
3. Ip S, Glicken S, Kulig J, O'Brien R, Sege R. Management of neonatal hyperbilirubinemia. Evidence report/technology assessment No. 65. Boston, MA: Tufts New England Medical Center Evidence-based Practice Center; 2003
4. American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. Pediatrics. 2004;114(3):874-877
5. Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage - mechanisms and management approaches. N Engl J Med. 2013;369(21):2021-2030
6. Bhutani VK, Johnson LH, Jeffrey Maisels M, et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol. 2004;24(10):650-662
7. Bjerre JV, Petersen JR, Ebbesen F. Surveillance of extreme hyperbilirubinaemia in Denmark. A method to identify the newborn infants. Acta Paediatr. 2008;97(8):1030-1034
8. Ebbesen F, Bjerre JV, Vandborg PK. Relation between serum bilirubin levels ≥450mmol/L and bilirubin encephalopathy; a Danish population-based study. Acta Paediatr. 2012;101(4):384-389
9. Ebbesen F, Andersson C, Verder H, et al. Extreme hyperbilirubinaemia in term and near-term infants in Denmark. Acta Paediatr. 2005;94(1):59-64
10. Manning D, Todd P, Maxwell M, Jane Platt M. Prospective surveillance study of severe hyperbilirubinaemia in the newborn in the UK and Ireland. Arch Dis Child Fetal Neonatal Ed. 2007;92(5):F342-F346
11. Zoubir S, Mieth RA, Berrut S, Roth-Kleiner M; Swiss Paediatric Surveillance Unit. Incidence of severe hyperbilirubinaemia in Switzerland: a nationwide population-based prospective study. Arch Dis Child Fetal Neonatal Ed. 2011;96(4):F310-F311
12. Gotink MJ, Benders MJ, Lavrijsen SW, Rodrigues Pereira R, Hulzebos CV, Dijk PH. Severe neonatal hyperbilirubinemia in the Netherlands. Neonatology. 2013;104(2):137-142
13. Newman TB, Liljestrand P, Escobar GJ. Infants with bilirubin levels of 30 mg/dL or more in a large managed care organization. Pediatrics. 2003;111(6 pt 1):1303-1311
14. Kuzniewicz MW, Escobar GJ, Newman TB. Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use. Pediatrics. 2009;124(4):1031-1039
15. Eggert LD, Wiedmeier SE, Wilson J, Christensen RD. The effect of instituting a prehospitaldischarge newborn bilirubin screening program in an 18-hospital health system. Pediatrics. 2006;117(5). Available at: www.pediatrics.org/cgi/content/full/117/5/e855
16. Christensen RD, Lambert DK, Henry E, et al. Unexplained extreme hyperbilirubinemia among neonates in a multihospital healthcare system. Blood Cells Mol Dis. 2013;50 (2):105-109
17. Mah MP, Clark SL, Akhigbe E, et al. Reduction of severe hyperbilirubinemia after institution of predischarge bilirubin screening. Pediatrics. 2010;125(5). Available at: www.pediatrics.org/cgi/content/full/125/5/e1143
18. Sgro M, Campbell DM, Kandasamy S, Shah V. Incidence of chronic bilirubin encephalopathy in Canada, 2007-2008. Pediatrics. 2012;130(4). Available at: www.pediatrics.org/cgi/content/full/130/4/e886
19. Brooks JC, Fisher-Owens SA, Wu YW, Strauss DJ, Newman TB. Evidence suggests there was not a "resurgence" of kernicterus in the 1990s. Pediatrics. 2011;127(4):672-679
20. Newman TB, Liljestrand P, Jeremy RJ, et al; Jaundice and Infant Feeding Study Team. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med. 2006;354(18):1889-1900
21. Escobar GJ, Fischer A, Kremers R, Usatin MS, Macedo AM, Gardner MN. Rapid retrieval of neonatal outcomes data: the Kaiser Permanente Neonatal Minimum Data Set. Qual Manag Health Care. 1997;5(4):19-33
22. Kuzniewicz MW, Escobar GJ, Wi S, Liljestrand P, McCulloch C, Newman TB. Risk factors for severe hyperbilirubinemia among infants with borderline bilirubin levels: a nested casecontrol study. J Pediatr. 2008;153(2):234-240
23. Algur N, Avraham I, Hammerman C, Kaplan M. Quantitative neonatal glucose-6-phosphate dehydrogenase screening: distribution, reference values, and classification by phenotype. J Pediatr. 2012;161(2):197-200
24. Newman TB, Kuzniewicz MW, Liljestrand P, Wi S, McCulloch C, Escobar GJ. Numbers needed to treat with phototherapy according to American Academy of Pediatrics guidelines. Pediatrics. 2009;123(5):1352-1359
25. Shapiro SM. Chronic bilirubin encephalopathy: diagnosis and outcome. Semin Fetal Neonatal Med. 2010;15(3):157-163
26. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2): 377-381
27. Watchko JF, Kaplan M, Stark AR, Stevenson DK, Bhutani VK. Should we screen newborns for glucose-6-phosphate dehydrogenase deficiency in the United States? J Perinatol. 2013;33(7):499-504
28. Burke BL, Robbins JM, Bird TM, Hobbs CA, Nesmith C, Tilford JM. Trends in hospitalizations for neonatal jaundice and kernicterus in the United States, 1988-2005. Pediatrics. 2009;123(2):524-532
29. Newman TB, Maisels MJ. Kernicterus incidence estimates unreliable. Pediatrics. 2009;123(2). Available at: http://pediatrics.aappublications.org/content/123/2/524/reply
30. Kuzniewicz M, Newman TB. Interaction of hemolysis and hyperbilirubinemia on neurodevelopmental outcomes in the collaborative perinatal project. Pediatrics. 2009; 123(3):1045-1050
31. Gamaleldin R, Iskander I, Seoud I, et al. Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia. Pediatrics. 2011;128(4). Available at: www.pediatrics.org/cgi/content/full/128/4/e925
32. Newman TB, Maisels MJ. Evaluation and treatment of jaundice in the term newborn: a kinder, gentler approach. Pediatrics. 1992;89(5 pt 1):809-818
33. Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency: a potential source of severe neonatal hyperbilirubinaemia and kernicterus. Semin Neonatol. 2002;7 (2):121-128
34. Bhutani VK, Johnson L. Synopsis report from the pilot USA Kernicterus Registry. J Perinatol. 2009;29(suppl 1):S4-S7
35. Frank JE. Diagnosis and management of G6PD deficiency. Am Fam Physician. 2005;72 (7):1277-1282
36. Singh H. Glucose-6-phosphate dehydrogenase deficiency: a preventable cause of mental retardation. Br Med J (Clin Res Ed). 1986;292(6517):397-398